Company Information

Market
HKEX GEM
Listing Date
2001-05-24
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
CNE100000130

Industry

Innovative Drugs & Biologics 2.03%
124 stocks in this industry
Down 91 Up 17
Industry RankingsValue (HKD)Rank
Revenue (Last FY)1.06B54/112
Net Profit (Last FY)233.88M40/125
ROE (Last FY)11.78%24/117

Change is the 2026-11-13 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
Zhang Yi Executive Director
Xu Xiang Fu Executive Director
Wang Wei Executive Director
Chi Chun Hong Executive Director
Li Ning Executive Director
Gao Qi Pin Independent Non-Executive Director
Bai Jun Gui Independent Non-Executive Director
Tian Jie Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-06-09.

About this page

This page shows JILIN CHANGLONG (08049) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect